AUTHORS
Richa Rai, PhD, Jonathan Feld, MD2, Richard Stephen Sheppard I, MD3, Kyle Wiatrowski I, MD4, Haocheng Yu I, Ph D5, Mahina Sheikh6, Michelle Rudshteyn Korostin, MD7, John Chris Ingles8, Daniel Salib9, Erin P Demakos I, RN10, Meenakshi Mehrotra, PhD11, Jane Houldsworth, PhD12, Shafinaz Hussein I, MD13, Diego Chowell I, Ph D14, Amir Horowitz I, Ph D15, Lewis R Silverman, MD16
AFFILIATIONS
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Moffitt Cancer Center at Memorial Healthcare System, Pembroke Pines, Florida, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Icahn School of Medicine at Mount Sinai, New York, New York, United States
8 Icahn School of Medicine at Mount Sinai, New York, New York, United States
9 Icahn School of Medicine at Mount Sinai, New York, New York, United States
10 Icahn School of Medicine at Mount Sinai, New York, New York, United States
11 Icahn School of Medicine at Mount Sinai, New York, New York, United States
12 Icahn School of Medicine at Mount Sinai, New York, New York, United States
13 Icahn School of Medicine at Mount Sinai, New York, New York, United States
14 Icahn School of Medicine at Mount Sinai, New York, New York, United States
15 Icahn School of Medicine at Mount Sinai, New York, New York, United States
16 Icahn School of Medicine at Mount Sinai, New York, New York, United States
ABSTRACT
Background:
Bone marrow failure (BMF) is the principal cause of morbidity in lower-risk myelodysplastic syndromes (MDS), yet current models emphasizing stem cell-intrinsic defects incompletely explain progressive cytopenias. Autoimmune manifestations occur in up to half of MDS patients, suggesting that immune-mediated mechanisms contribute to hematopoietic dysfunction. We investigated whether expansion of CD16 (FcγRIIIa)-expressing innate immune populations represents a previously unrecognized immune-effector axis driving BMF. Because CD16 mediates antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), dysregulated Fc-dependent immune responses could represent a therapeutically targetable mechanism of marrow injury independent of the underlying myeloid clone.
Methods:
Clinical flow cytometry was performed on paired bone marrow and peripheral blood samples from 384 MDS patients to quantify more than twenty immune populations. Single-cell RNA sequencing with matched TCR sequencing and single-nucleus ATAC-seq was performed on bone marrow mononuclear cells (BMMCs) from six lower-risk MDS patients and three age-matched healthy controls. CyTOF profiling was performed on bone marrow specimens from 19 MDS patients (10 lower/intermediate-risk; 9 high-risk) and controls. Functional autologous bone marrow killing assays were performed using IncuCyte imaging with CD16 depletion and patient-derived IgG. Clinical outcomes were retrospectively analyzed in 41 MDS patients with autoimmune cytopenias and LGL expansion treated with intravenous immunoglobulin (IVIG), with TCR clonality assessed in a subset.
Results:
Across multiple independent cohorts and profiling platforms, we identified coordinated expansion of CD16-expressing innate immune populations in MDS. Clinical flow cytometry demonstrated marked expansion of CD16++ non-classical (CD14-/dim) monocytes that were strongly associated with clinical measures of bone marrow failure (P<0.01). Single-cell analyses confirmed expansion of monocyte populations within lower-risk MDS, with intermediate monocyte abundance correlating with TET2 mutations (P<0.001). Strikingly, abundance of CD16++ non-classical (CD14-/dim) monocytes was inversely correlated with myeloblast burden (p<0.05).
In parallel, CyTOF and single-cell analyses demonstrated expansion of CD57+ NK cells and CD57+ CD8+ large granular lymphocytes (LGLs) exhibiting a highly activated innate-like phenotype characterized by expression of CD16, NKG2A, KIR receptors, NKG2D, perforin, granzymes, and inflammatory cytokines. Compared with age-matched healthy controls, innate-like CD8+ T cells demonstrated significantly enhanced cytotoxic programs (P<0.0001).
Functional studies demonstrated that autologous bone marrow-derived IgG induced robust CD16-dependent ADCC against autologous marrow cells, whereas CD16 depletion or IVIG markedly reduced cytotoxic activity, identifying Fc-dependent activation of innate immune effectors as a mechanism of marrow injury. Consistent with these findings, IVIG treatment of patients with severe BMF and LGL expansion produced an overall hematologic response rate of 73% (16/22). Among patients with confirmed clonal LGL expansion by TCR sequencing, hematologic responses reached 80%, compared with 25% in patients without detectable clonality. In a larger cohort of 41 MDS patients treated with IVIG, there was a trend toward improved OS in those who had a hematologic response (n=26) vs non-responders (n=15) (HR: 0.405, 95% CI 0.14-1.19).
Conclusion:
These orthogonal clinical, single-cell, functional, and translational studies identify expansion of multiple CD16-expressing innate immune populations—including intermediate and non-classical monocytes, CD57+ NK cells, and innate-like CD57+ CD8 LGLs—as a previously unrecognized feature of lower-risk MDS associated with bone marrow failure. These immune populations exhibit a shared FcγRIIIa (CD16)-dependent effector program that promotes immune-mediated hematopoietic injury. The concordance between functional CD16 perturbation, inhibition of autologous ADCC, and clinical responses to IVIG supports CD16-dependent innate effector function as a therapeutically targetable mechanism for restoring hematopoiesis in MDS.
DISCLOSURES
Richa Rai, PhD: No relevant conflicts of interest to declare.